Cargando…
Vitamin C sensitizes BRAF(V600E) thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032
BACKGROUND: BRAFV600E mutation is the most common mutation in thyroid cancer. It strongly activates MAPK/ERK pathway and indicates an invasive subtype of thyroid cancer. PLX4032 is a selective oral inhibitor of the BRAFV600 kinase although with limited effect in treating this panel of thyroid cancer...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816401/ https://www.ncbi.nlm.nih.gov/pubmed/33468157 http://dx.doi.org/10.1186/s13046-021-01831-y |
_version_ | 1783638435371679744 |
---|---|
author | Su, Xi Li, Peng Han, Bin Jia, Hao Liang, Qingzhuang Wang, Haichao Gu, Mengwei Cai, Jiaxuan Li, Shaolei Zhou, Yaqi Yi, Xin Wei, Wei |
author_facet | Su, Xi Li, Peng Han, Bin Jia, Hao Liang, Qingzhuang Wang, Haichao Gu, Mengwei Cai, Jiaxuan Li, Shaolei Zhou, Yaqi Yi, Xin Wei, Wei |
author_sort | Su, Xi |
collection | PubMed |
description | BACKGROUND: BRAFV600E mutation is the most common mutation in thyroid cancer. It strongly activates MAPK/ERK pathway and indicates an invasive subtype of thyroid cancer. PLX4032 is a selective oral inhibitor of the BRAFV600 kinase although with limited effect in treating this panel of thyroid cancer, due to the feedback activation of MAPK/ERK as well as PI3K/AKT pathways. It was investigated that Vitamin C plays a positive role in inhibiting these pathways in thyroid cancer. However, whether Vitamin C could enhance the antitumor effect of PLX4032 remains largely unclear. METHODS: The antitumor efficacy of combination therapy with PLX4032 and Vitamin C on BRAF(MT) thyroid cancer cell was assessed by the MTT assay, EdU assay and colony formation, Chou-Talalay way was employed to analyze the synergistic effect. Flow cytometry were employed to assess cells’ apoptosis and cell cycle arrest in response to combination therapy. Xenograft models were used to test its in vivo antitumor activity. Western blot and IHC were applied to investigate the mechanism underlying synergistic effect. RESULTS: PLX4032 or Vitamin C monotherapy was mildly effective in treating BRAF(MT) thyroid cancer cell and xenografts model. The combination therapy significantly inhibited cancer cell proliferation and tumor growth in nude mice, and induced cell apoptosis and cell cycle arrest compared to either monotherapy. PLX4032 monotherapy induced feedback activation of MAPK/ERK as well as PI3K/AKT pathway; while combination therapy significantly relieved this feedback. CONCLUSION: Vitamin C promotes the antitumor effect of PLX4032 in BRAF(MT) thyroid cancer cell and xenografts model via relieving the feedback activation of MAPK/ERK as well as PI3K/AKT pathway. PLX4032/Vitamin C combination may be a potential therapeutic approach to treat BRAF(MT) thyroid cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-021-01831-y. |
format | Online Article Text |
id | pubmed-7816401 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-78164012021-01-21 Vitamin C sensitizes BRAF(V600E) thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032 Su, Xi Li, Peng Han, Bin Jia, Hao Liang, Qingzhuang Wang, Haichao Gu, Mengwei Cai, Jiaxuan Li, Shaolei Zhou, Yaqi Yi, Xin Wei, Wei J Exp Clin Cancer Res Research BACKGROUND: BRAFV600E mutation is the most common mutation in thyroid cancer. It strongly activates MAPK/ERK pathway and indicates an invasive subtype of thyroid cancer. PLX4032 is a selective oral inhibitor of the BRAFV600 kinase although with limited effect in treating this panel of thyroid cancer, due to the feedback activation of MAPK/ERK as well as PI3K/AKT pathways. It was investigated that Vitamin C plays a positive role in inhibiting these pathways in thyroid cancer. However, whether Vitamin C could enhance the antitumor effect of PLX4032 remains largely unclear. METHODS: The antitumor efficacy of combination therapy with PLX4032 and Vitamin C on BRAF(MT) thyroid cancer cell was assessed by the MTT assay, EdU assay and colony formation, Chou-Talalay way was employed to analyze the synergistic effect. Flow cytometry were employed to assess cells’ apoptosis and cell cycle arrest in response to combination therapy. Xenograft models were used to test its in vivo antitumor activity. Western blot and IHC were applied to investigate the mechanism underlying synergistic effect. RESULTS: PLX4032 or Vitamin C monotherapy was mildly effective in treating BRAF(MT) thyroid cancer cell and xenografts model. The combination therapy significantly inhibited cancer cell proliferation and tumor growth in nude mice, and induced cell apoptosis and cell cycle arrest compared to either monotherapy. PLX4032 monotherapy induced feedback activation of MAPK/ERK as well as PI3K/AKT pathway; while combination therapy significantly relieved this feedback. CONCLUSION: Vitamin C promotes the antitumor effect of PLX4032 in BRAF(MT) thyroid cancer cell and xenografts model via relieving the feedback activation of MAPK/ERK as well as PI3K/AKT pathway. PLX4032/Vitamin C combination may be a potential therapeutic approach to treat BRAF(MT) thyroid cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-021-01831-y. BioMed Central 2021-01-19 /pmc/articles/PMC7816401/ /pubmed/33468157 http://dx.doi.org/10.1186/s13046-021-01831-y Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Su, Xi Li, Peng Han, Bin Jia, Hao Liang, Qingzhuang Wang, Haichao Gu, Mengwei Cai, Jiaxuan Li, Shaolei Zhou, Yaqi Yi, Xin Wei, Wei Vitamin C sensitizes BRAF(V600E) thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032 |
title | Vitamin C sensitizes BRAF(V600E) thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032 |
title_full | Vitamin C sensitizes BRAF(V600E) thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032 |
title_fullStr | Vitamin C sensitizes BRAF(V600E) thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032 |
title_full_unstemmed | Vitamin C sensitizes BRAF(V600E) thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032 |
title_short | Vitamin C sensitizes BRAF(V600E) thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032 |
title_sort | vitamin c sensitizes braf(v600e) thyroid cancer to plx4032 via inhibiting the feedback activation of mapk/erk signal by plx4032 |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816401/ https://www.ncbi.nlm.nih.gov/pubmed/33468157 http://dx.doi.org/10.1186/s13046-021-01831-y |
work_keys_str_mv | AT suxi vitamincsensitizesbrafv600ethyroidcancertoplx4032viainhibitingthefeedbackactivationofmapkerksignalbyplx4032 AT lipeng vitamincsensitizesbrafv600ethyroidcancertoplx4032viainhibitingthefeedbackactivationofmapkerksignalbyplx4032 AT hanbin vitamincsensitizesbrafv600ethyroidcancertoplx4032viainhibitingthefeedbackactivationofmapkerksignalbyplx4032 AT jiahao vitamincsensitizesbrafv600ethyroidcancertoplx4032viainhibitingthefeedbackactivationofmapkerksignalbyplx4032 AT liangqingzhuang vitamincsensitizesbrafv600ethyroidcancertoplx4032viainhibitingthefeedbackactivationofmapkerksignalbyplx4032 AT wanghaichao vitamincsensitizesbrafv600ethyroidcancertoplx4032viainhibitingthefeedbackactivationofmapkerksignalbyplx4032 AT gumengwei vitamincsensitizesbrafv600ethyroidcancertoplx4032viainhibitingthefeedbackactivationofmapkerksignalbyplx4032 AT caijiaxuan vitamincsensitizesbrafv600ethyroidcancertoplx4032viainhibitingthefeedbackactivationofmapkerksignalbyplx4032 AT lishaolei vitamincsensitizesbrafv600ethyroidcancertoplx4032viainhibitingthefeedbackactivationofmapkerksignalbyplx4032 AT zhouyaqi vitamincsensitizesbrafv600ethyroidcancertoplx4032viainhibitingthefeedbackactivationofmapkerksignalbyplx4032 AT yixin vitamincsensitizesbrafv600ethyroidcancertoplx4032viainhibitingthefeedbackactivationofmapkerksignalbyplx4032 AT weiwei vitamincsensitizesbrafv600ethyroidcancertoplx4032viainhibitingthefeedbackactivationofmapkerksignalbyplx4032 |